Evidence map›Paper›PMID 15802018›Full record

ArticleNeoplasia (New York, N.Y.)2005

Resveratrol and estradiol exert disparate effects on cell migration, cell surface actin structures, and focal adhesion assembly in MDA-MB-231 human breast cancer cells.

Nicolas G Azios, Suranganie F Dharmawardhane

Open access · goldAbstract read
In one paragraph

Article in Neoplasia (New York, N.Y.), 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 95 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. From plasminogen to plasmin: role of plasminogen receptors in human cancer.International journal of molecular sciences · 2014
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Nicolas G AziosMolecular Cell and Developmental Biology Section and Institute for Cellular and Molecular Biology, The University of Texas at Austin, Austin, TX 78712, USA.
Suranganie F Dharmawardhane
The University of Texas at Austin · US

Funding

REGULATORY ROLE OF RAC AND CDC42 ON TUMOR METASTASISR21CA083957 · NCI · UNIVERSITY OF TEXAS AUSTIN · PI DHARMAWARDHANE, SURANGANIE F · 2000 to 2001
$225k
Resveratrol in breast cancer cell survival or apoptosisR03CA109913 · NCI · UNIVERSIDAD CENTRAL DEL CARIBE · PI DHARMAWARDHANE, SURANGANIE F · 2005 to 2006
$143k
NCI NIH HHS CA83957-01A1NCI NIH HHS R03 CA109913
6 · The paper itself

Abstract

Resveratrol, a grape polyphenol, is thought to be a cancer preventive, yet its effects on metastatic breast cancer are relatively unknown. Since cancer cell invasion is dependent on cell migration, the chemotactic response of MDA-MB-231 metastatic human breast cancer cells to resveratrol, estradiol (E2), or epidermal growth factor (EGF) was investigated. Resveratrol decreased while E2 and EGF increased directed cell migration. Resveratrol may inhibit cell migration by altering the cytoskeleton. Resveratrol induced a rapid global array of filopodia and decreased focal adhesions and focal adhesion kinase (FAK) activity. E2 or EGF treatment did not affect filopodia extension but increased lamellipodia and associated focal adhesions that are integral for cell migration. Combined resveratrol and E2 treatment resulted in a filopodia and focal adhesion response similar to resveratrol alone. Combined resveratrol and EGF resulted in a lamellipodia and focal adhesion response similar to EGF alone. E2 and to a lesser extent resveratrol increased EGFR activity. The cytoskeletal changes and EGFR activity in response to E2 were blocked by EGFR1 inhibitor indicating that E2 may increase cell migration via crosstalk with EGFR signaling. These data suggest a promotional role for E2 in breast cancer cell migration but an antiestrogenic, preventative role for resveratrol.

Indexed as

ActinsAngiogenesis InhibitorsAntineoplastic Agents, PhytogenicBreast NeoplasmsCell MembraneCell MovementCytoskeletonEpidermal Growth FactorErbB ReceptorsEstradiolEstrogen Receptor alphaEstrogen Receptor betaFemaleFocal Adhesion Kinase 1Focal Adhesion Protein-Tyrosine KinasesFocal AdhesionsActinsAngiogenesis InhibitorsAntineoplastic Agents, PhytogenicEpidermal Growth FactorErbB ReceptorsEstradiolEstrogen Receptor alphaEstrogen Receptor betaFocal Adhesion Kinase 1Focal Adhesion Protein-Tyrosine KinasesProtein-Tyrosine KinasesPTK2 protein, humanResveratrolStilbenes

Identifiers

PMID15802018
PMCPMC1501122
OpenAlexW1971002820

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.